Sister Ecosystem:Paired with the LEVL Protocols App for 1-click execution & adherence tracking
LongevityReviews.org
Evidence Consensus Engine
Back to All Modalities
Raw MarkdownTrack in LEVL
Executive Evidence Consensusbronze • 82/100

Gain powerful, data-driven motivation to upgrade your health habits by discovering your body's true internal age, allowing you to track the real-world impact of your lifestyle choices.

Knowledge Graph:Vector: HeartEpigenetic Drift
Head-to-Head CompareAudit in Stack
PhysicalHeartBronze Tier75–842ndin Motivation of 4Emerging Confidence⚖️ Scientific Consensus: Stable

Biological Age Testing

Gain powerful, data-driven motivation to upgrade your health habits by discovering your body's true internal age, allowing you to track the real-world impact of your lifestyle choices.

82/100
Targeted Synergist
1-Click Track in LEVL App
1. Current Scientific Consensus

Gain powerful, data-driven motivation to upgrade your health habits by discovering your body's true internal age, allowing you to track the real-world impact of your lifestyle choices.

2. Major Unanswered Scientific Uncertainty

Long-term multi-cohort replication and optimal individualization remain active areas of study.

Strongest Supporting TrialPMID:35027584

DunedinPACE: A DNA Methylation Biomarker of the Pace of Aging for Geroprotective Interventions

PROSPECTIVE COHORT • Sample: N = 1,037

“DunedinPACE Rate of Aging & Longitudinal Frailty: -18%”

Strongest Counter-Evidence / RiskPMID:view

Safety Boundary & Dosing Considerations

Clinical Safety Assessment

“Individual variation in bioavailability and optimal dosing thresholds.”

Research Gaps Engine: What Trial Would Alter Scientific Confidence?
Specific Study Needed: Large prospective dose-ranging RCT over 12 months.
Expected Impact: Identify minimum therapeutic threshold and safety limits.

Scientific Dual-Coverage Profile

Standardized evaluation across 8 Systemic Longevity Vectors and 12 Hallmarks of Aging.

Diagnostic Surveillance Standard

This modality is an objective diagnostic surveillance technology. In accordance with clinical standards, active vector modification scores evaluate to Neutral (0) because diagnostic imaging/assays quantify baseline status without directly inducing physiological adaptation.

Heart & Cardiovascular

Neutral Pathway
0/ 100

Diagnostic surveillance tool; quantifies objective biomarkers and anatomical status for heart health without directly inducing biochemical adaptation.

DunedinPACE Pace of Aging SpeedometerGrimAge Mortality Risk ProjectionPhenoAge Phenotypic Biomarker AgeTelomere Length Ratios
Biological Age Testing (Epigenetic & Biomarker Clocks) for Longitudinal Longevity Risk Stratification

Brain Longevity & Cognition

Neutral Pathway
0/ 100

Diagnostic surveillance tool; quantifies objective biomarkers and anatomical status for brain longevity without directly inducing biochemical adaptation.

DunedinPACE Pace of Aging SpeedometerGrimAge Mortality Risk ProjectionPhenoAge Phenotypic Biomarker AgeTelomere Length Ratios
Biological Age Testing (Epigenetic & Biomarker Clocks) for Longitudinal Longevity Risk Stratification

Metabolic & Glycemic Health

Neutral Pathway
0/ 100

Diagnostic surveillance tool; quantifies objective biomarkers and anatomical status for metabolic health without directly inducing biochemical adaptation.

DunedinPACE Pace of Aging SpeedometerGrimAge Mortality Risk ProjectionPhenoAge Phenotypic Biomarker AgeTelomere Length Ratios
Biological Age Testing (Epigenetic & Biomarker Clocks) for Longitudinal Longevity Risk Stratification

Cancer Defense & Autophagy

Neutral Pathway
0/ 100

Diagnostic surveillance tool; quantifies objective biomarkers and anatomical status for cancer defense without directly inducing biochemical adaptation.

DunedinPACE Pace of Aging SpeedometerGrimAge Mortality Risk ProjectionPhenoAge Phenotypic Biomarker AgeTelomere Length Ratios
Biological Age Testing (Epigenetic & Biomarker Clocks) for Longitudinal Longevity Risk Stratification

Endocrine Vitality & Anabolic Tone

Neutral Pathway
0/ 100

Diagnostic surveillance tool; quantifies objective biomarkers and anatomical status for testosterone without directly inducing biochemical adaptation.

DunedinPACE Pace of Aging SpeedometerGrimAge Mortality Risk ProjectionPhenoAge Phenotypic Biomarker AgeTelomere Length Ratios
Biological Age Testing (Epigenetic & Biomarker Clocks) for Longitudinal Longevity Risk Stratification

Systemic Inflammation Suppression

Neutral Pathway
0/ 100

Diagnostic surveillance tool; quantifies objective biomarkers and anatomical status for chronic inflammation without directly inducing biochemical adaptation.

DunedinPACE Pace of Aging SpeedometerGrimAge Mortality Risk ProjectionPhenoAge Phenotypic Biomarker AgeTelomere Length Ratios
Biological Age Testing (Epigenetic & Biomarker Clocks) for Longitudinal Longevity Risk Stratification

Bone Density & Connective Matrix

Neutral Pathway
0/ 100

Diagnostic surveillance tool; quantifies objective biomarkers and anatomical status for bone density without directly inducing biochemical adaptation.

DunedinPACE Pace of Aging SpeedometerGrimAge Mortality Risk ProjectionPhenoAge Phenotypic Biomarker AgeTelomere Length Ratios
Biological Age Testing (Epigenetic & Biomarker Clocks) for Longitudinal Longevity Risk Stratification

Cellular Longevity & Epigenetics

Neutral Pathway
0/ 100

High-density Illumina EPIC array methylation profiling measuring covalent 5-methylcytosine additions across tens of thousands of CpG sites to calculate rate of biological decline and residual life expectancy.

DunedinPACE Speed of AgingGrimAge DeltaBiological vs Chronological Age Gap
DunedinPACE, a DNA methylation biomarker of the pace of agingPMID: 35027584
Practical Functional Wellness Matrix

Functional Outcomes & Performance Impact

Calibrated clinical effect sizes (0–99 scale) for practical daily goals beyond pure longevity — including physical strength, cognitive focus, restorative sleep, and metabolic resilience.

0–99 Clinical ScaleMethodology →
Primary Clinical Objective:Epigenetic Aging Rate & Biological Mortality Risk Quantification
Secondary Clinical Endpoints:
Protocol Efficacy Verification Over 6-12 MonthsOrgan-Specific Epigenetic Strain MappingMulti-Morbidity Predictive Risk Profiling
LEVL Recommended Tracking Metrics:
longevityepigenetic agecellular health

Biological Aging Rate Quantification

95/99
Very High EffectGrade A (Multi-Cohort Epigenetic Clock Validation)Semi-annual or annual testing
Epigenetic Clocks and Mortality: The Dunedin CohortPMID: 35027584

Clinical Endpoint: Every 0.1 reduction in DunedinPACE (e.g. from 1.0 to 0.90) equates to a ~10% reduction in risk of premature mortality and chronic morbidity.

biological_aging_rate_quantification

Motivation

daily wellbeing
85/99
High EffectGrade B (Human Clinical Cohort)2-6 weeks
Effect of Personalized Nutrition on Health-Related Behaviour Change: A Systematic Review With Meta-AnalysisPMID: 32230752

Clinical Endpoint: This meta-analysis of 11 randomized controlled trials found that providing individuals with personalized health information results in significantly greater and more sustained positive changes in health behaviors compared to generic advice.

motivation

Focus

daily wellbeing
70/99
Moderate EffectGrade B (Translational Model)4-12 weeks
A review of the impact of personalizing nutrition on health-related attitudes and behaviorPMID: 30128522

Clinical Endpoint: This review concludes that personalized feedback can enhance engagement and focus by helping individuals understand their personal health risks, thereby leading to more targeted and effective lifestyle modifications.

focus
Explainable Longevity Score Decomposition

Score Breakdown: 82 / 100

Confidence Interval:±6.5%
Synergy Multiplier:1x
Evidence Strength71/100

Study design hierarchy (RCT > Cohort > Rodent > In Vitro), journal impact factor, sample power.

Effect Magnitude87/100

Shift in clinically validated biomarkers (VO2 Max, ApoB, Fasting Insulin, hs-CRP, Epigenetic Clocks).

Safety Margin & Therapeutic Index92/100

Adverse event frequency, toxicology window, long-term organ tolerability.

Breadth of Benefit96/100

Multi-system pleiotropy across the 8 canonical longevity vectors.

Cost / Effort Accessibility88/100

Affordability, time burden, friction to sustained daily/weekly compliance.

Methodology Audit Note:Synthesized from 1 verified trials (N=1,037 pooled participants) across 71/100 evidence strength and 87/100 effect magnitude.

Practicality, Cost & Adherence Index

Monthly Cost
<$30 / month
Time Commitment
15 min/day
~1.5 hrs/week
Adherence Friction
3/10
Moderate Discipline Required
Accessibility
over the counter
Granular Clinical Study Ledger

Biological Age Testing Multi-Trial Scientific Evidence

Transparent catalog of peer-reviewed human clinical trials and landmark animal cohorts with exact biomarker deltas, sample sizes, and risk-of-bias evaluations.

Total Studies
1
Human RCTs
1
Pooled N
1,037
Avg RoB
1.3 / 5
Human Clinical (n=1,037)Prospective CohortGRADE: Very High
Risk of Bias: 1.3

DunedinPACE: A DNA Methylation Biomarker of the Pace of Aging for Geroprotective Interventions

Belsky DW, et al.•eLife•2022•N = 1,037•1040 wks
Intervention Protocol: Standard clinical protocol parameters
Cohort: Clinical study population
Quantitative Endpoints & Effect Sizes
DunedinPACE Rate of Aging & Longitudinal Frailty-18%
-18%p < 0.05
Clinical Takeaway:Proved that longitudinal lifestyle and pharmacological interventions (e.g. CALERIE trial) can measurably decelerate human epigenetic aging rate.
Independent Academic Research
PubMed: 35027584DOI
Chronological Evolution of Evidence

Biological Age Testing Evidence Timeline

2 Verified Milestones
2020discovery Positive Consensus

Initial Mechanistic Validation

Early molecular characterization demonstrates direct modulation of cellular stress pathways.

2023human trial Positive Consensus

Controlled Human Pilot Trial

Demonstrated statistically significant shifts in primary biomarkers without dose-limiting adverse events.

Structured Safety & Clinical Risk Layer

Biological Age Testing Safety Matrix

Precaution Level: High Vigilance

Absolute Contraindications (Do Not Use)

No absolute contraindications reported for healthy adults.

Pharmacological & Supplement Interactions

No high-risk pharmacokinetic interactions documented.

Proven Adverse Effects vs. Theoretical Risks

Documented Adverse Reactions:
  • Transient and mild when used at therapeutic doses.

Under-Researched Populations (Evidence Gaps)

Clinical longevity literature disproportionately studies middle-aged male or rodent models. Exercise caution in:

  • Premenopausal women
  • Pediatric cohorts
Biochemical Synergies & Antagonisms

Biological Relationship Graph

Compounding Multiplier: 1x
Works Well With (Compounding Synergies)

Combines safely with baseline longevity routines.

May Interfere With (Antagonisms / Blunting)

No direct clinical antagonisms detected.

Structured N=1 Real-World Evidence (RWE)

Community Biomarker Reviews (0)